PMID- 16778834
OWN - NLM
STAT- MEDLINE
DCOM- 20070316
LR  - 20161124
IS  - 1350-9047 (Print)
IS  - 1350-9047 (Linking)
VI  - 14
IP  - 2
DP  - 2007 Feb
TI  - Downregulation of Bim by brain-derived neurotrophic factor activation of TrkB 
      protects neuroblastoma cells from paclitaxel but not etoposide or 
      cisplatin-induced cell death.
PG  - 318-26
AB  - Chemoresistance and increased expression of TrkB and brain-derived neurotrophic 
      factor (BDNF) are biomarkers of poor prognosis in tumors from patients with 
      neuroblastoma (NB). Previously, we found BDNF activation of TrkB through PI3K/Akt 
      protects NB from etoposide/cisplatin-induced cell death. In this study, the role 
      of Bim, a proapoptotic protein, was investigated. Bim was involved in paclitaxel 
      but not etoposide or cisplatin-induced cell death in NB cells. Pharmacological 
      and genetic studies showed that BDNF-induced decreases in Bim were regulated by 
      MAPK and not PI3K/Akt pathway. Both MAPK and PI3K pathways were involved in BDNF 
      protection of NB cells from paclitaxel-induced cell death, while PI3K 
      predominantly mediated BDNF protection of NB cells from etoposide or 
      cisplatin-induced cell death. These data indicate that different chemotherapeutic 
      drugs induce distinct death pathways and growth factors utilize different signal 
      transduction pathways to modulate the effects of chemotherapy on cells.
FAU - Li, Z
AU  - Li Z
AD  - Cell & Molecular Biology Section, Pediatric Oncology Branch, Center for Cancer 
      Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 
      20892, USA.
FAU - Zhang, J
AU  - Zhang J
FAU - Liu, Z
AU  - Liu Z
FAU - Woo, C-W
AU  - Woo CW
FAU - Thiele, C J
AU  - Thiele CJ
LA  - eng
GR  - Intramural NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Intramural
DEP - 20060616
PL  - England
TA  - Cell Death Differ
JT  - Cell death and differentiation
JID - 9437445
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Apoptosis Regulatory Proteins)
RN  - 0 (BCL2L11 protein, human)
RN  - 0 (Bcl-2-Like Protein 11)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (FOXO3 protein, human)
RN  - 0 (Forkhead Box Protein O3)
RN  - 0 (Forkhead Transcription Factors)
RN  - 0 (Membrane Proteins)
RN  - 0 (Protein Isoforms)
RN  - 0 (Proto-Oncogene Proteins)
RN  - 0 (RNA, Messenger)
RN  - 0 (RNA, Small Interfering)
RN  - 6PLQ3CP4P3 (Etoposide)
RN  - EC 2.7.1.- (Phosphatidylinositol 3-Kinases)
RN  - EC 2.7.10.1 (Receptor, trkB)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinases)
RN  - P88XT4IS4D (Paclitaxel)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Antineoplastic Agents/*pharmacology
MH  - Apoptosis Regulatory Proteins/genetics/*metabolism
MH  - Bcl-2-Like Protein 11
MH  - Brain-Derived Neurotrophic Factor/*pharmacology
MH  - Cell Death/drug effects
MH  - Cisplatin/pharmacology
MH  - Down-Regulation/*drug effects
MH  - Enzyme Activation/drug effects
MH  - Etoposide/pharmacology
MH  - Forkhead Box Protein O3
MH  - Forkhead Transcription Factors/metabolism
MH  - Gene Expression Regulation, Enzymologic/drug effects
MH  - Gene Expression Regulation, Neoplastic/drug effects
MH  - Gene Silencing
MH  - Humans
MH  - Membrane Proteins/genetics/*metabolism
MH  - Mitogen-Activated Protein Kinases/metabolism
MH  - Molecular Mimicry/drug effects
MH  - Neuroblastoma/*enzymology/genetics/*pathology
MH  - Paclitaxel/pharmacology
MH  - Phosphatidylinositol 3-Kinases/metabolism
MH  - Phosphorylation/drug effects
MH  - Protein Isoforms/genetics/metabolism
MH  - Proto-Oncogene Proteins/genetics/*metabolism
MH  - RNA, Messenger/genetics/metabolism
MH  - RNA, Small Interfering/metabolism
MH  - Receptor, trkB/genetics/*metabolism
EDAT- 2006/06/17 09:00
MHDA- 2007/03/17 09:00
CRDT- 2006/06/17 09:00
PHST- 2006/06/17 09:00 [pubmed]
PHST- 2007/03/17 09:00 [medline]
PHST- 2006/06/17 09:00 [entrez]
AID - 4401983 [pii]
AID - 10.1038/sj.cdd.4401983 [doi]
PST - ppublish
SO  - Cell Death Differ. 2007 Feb;14(2):318-26. doi: 10.1038/sj.cdd.4401983. Epub 2006 
      Jun 16.